What's in a Perspective?
Abstract
The history of pharmaceutical costing for use in costeffectiveness studies has been marked more by convenience— what pricing data are readily available?—than by science—what
opportunities are forgone when we use a particular drug? For too long, our field has relied on average wholesale price, when there is substantial evidence that it is an inappropriate measure [1,2]. Thus, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force on Good Research Practices—Use of Drug Costs for Cost Effectiveness Analysis reports on drug costing [3–8] is commendable.
opportunities are forgone when we use a particular drug? For too long, our field has relied on average wholesale price, when there is substantial evidence that it is an inappropriate measure [1,2]. Thus, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force on Good Research Practices—Use of Drug Costs for Cost Effectiveness Analysis reports on drug costing [3–8] is commendable.
Authors
Henry A. Glick